8-K: Ovid Therapeutics Provides Business Update and First Quarter 2024 Financial Results

Ovid Therapeutics reported its first quarter 2024 financial results and provided updates on its clinical pipeline, including progress on soticlestat, OV888, and OV329.

Summary

• Ovid Therapeutics announced its first quarter 2024 financial results, with a net loss of $11.7 million, or $0.17 per share, compared to a net loss of $13.4 million, or $0.19 per share, for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $90.3 million as of March 31, 2024, which is expected to fund operations into the first half of 2026.
• Ovid's revenue for the quarter was $148,000, up from $66,000 in the same period last year, primarily from royalty and licensing agreements.
• Research and development expenses increased to $10.4 million, up from $6.6 million in the first quarter of 2023, due to the advancement of clinical programs.
• General and administrative expenses decreased to $7.2 million, down from $8.3 million in the same period last year, due to reductions in full-time employees.
• Takeda has completed two Phase 3 trials for soticlestat, with topline data expected in Takeda's H1 2024 fiscal year (by or before September 2024).
• Ovid expects to initiate a Phase 2 clinical program for OV888 (GV101) in cerebral cavernous malformations in the second half of 2024.
• The company is also advancing two development programs for OV329, with data expected from a Phase 1 study in late 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a solid cash position, but also acknowledges the inherent risks and ongoing losses associated with drug development.

Positives

• Ovid's cash position of $90.3 million is expected to fund operations into H1 2026.
• Revenue increased to $148,000 from $66,000 in the same quarter last year.
• General and administrative expenses decreased year-over-year.
• The company has multiple clinical programs advancing with key milestones expected this year.
• Ovid retains a significant financial interest in soticlestat, with potential for substantial milestone payments and royalties.
• The Phase 1 study of OV888 (GV101) showed no serious adverse events.

Negatives

• Ovid reported a net loss of $11.7 million for the first quarter of 2024.
• Research and development expenses increased to $10.4 million, up from $6.6 million in the same period last year.
• The company is still reliant on external partners for the development of soticlestat.

Risks

• The success of Ovid's pipeline programs is dependent on positive clinical trial results and regulatory approvals.
• Ovid's financial performance is subject to the inherent risks of drug development and commercialization.
• The company's ability to achieve its financial objectives is subject to market conditions and other factors.
• There is a risk that Ovid may not be able to realize the intended benefits of its technology or business strategy.
• Ovid may not be able to identify business development targets or strategic partners, or enter into strategic transactions on favorable terms.

Future Outlook

Ovid anticipates multiple data and regulatory milestones before year-end, including topline data from Takeda's soticlestat trials, safety data from the OV888 Phase 1 study, and the initiation of a Phase 2 study for OV888. The company expects its cash runway to support operations into H1 2026.

Management Comments

• Jeremy Levin, Chairman and CEO of Ovid Therapeutics, stated that this is an exhilarating period for Ovid and that their innovative programs are progressing through clinical trials.
• Dr. Levin also mentioned that they are eagerly anticipating the outcomes of Takeda's Phase 3 studies of soticlestat, which could herald a new class of anti-seizure medication.
• Dr. Levin noted that their collaboration with Graviton Bioscience has been highly fruitful and they are planning to launch a Phase 2 study for their ROCK2 inhibition program.

Industry Context

This announcement reflects the ongoing efforts in the biopharmaceutical industry to develop new treatments for rare neurological conditions. Ovid's focus on targeted small molecules and its collaboration with Takeda and Graviton Bioscience are consistent with industry trends towards precision medicine and strategic partnerships.

Comparison to Industry Standards

• Ovid's research and development spending of $10.4 million for the quarter is typical for a clinical-stage biopharmaceutical company, but is lower than larger companies with more advanced pipelines.
• The company's cash runway into H1 2026 is a positive sign, as many smaller biotech companies face funding challenges.
• The potential for $660 million in milestone payments and royalties from soticlestat is significant, but is contingent on successful clinical trials and regulatory approvals, similar to other biotech companies with partnered assets.
• The development of OV888, OV329, and OV350 aligns with the industry's focus on novel therapies for neurological disorders, but these programs are still in early stages compared to some competitors with more advanced clinical pipelines.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the potential for future revenue from soticlestat.
• Employees may be impacted by the company's focus on advancing its pipeline and potential future growth.
• Patients with rare epilepsies and brain conditions may benefit from the development of new treatments.
• Suppliers and creditors may be impacted by the company's financial performance and cash runway.

Next Steps

• Takeda will release topline data from the Phase 3 trials of soticlestat.
• Ovid will release topline safety data from the Phase 1 study of OV888.
• Ovid will initiate a Phase 2 clinical program for OV888 in cerebral cavernous malformations.
• Ovid will release data from the Phase 1 study of OV329.
• Ovid will submit an IND application for an IV formulation of OV329.
• Ovid will submit an IND application for an IV formulation of OV350.

Key Dates

Keywords

Ovid Therapeutics, soticlestat, OV888, OV329, OV350, epilepsy, clinical trials, biopharmaceutical, neurological disorders, Lennox-Gastaut syndrome, Dravet syndrome, cerebral cavernous malformations, ROCK2 inhibitor, GABA-aminotransferase inhibitor, KCC2 activator